deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02034110

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

Sponsor: Novartis Pharmaceuticals

Conditions Cancer
Interventions Dabrafenib Trametinib
Updated 22 times since 2017 Last updated: Jul 24, 2023 Started: Mar 12, 2014 Primary completion: Dec 10, 2021 Completion: Dec 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02034110, this PHASE2 trial focuses on Cancer and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 22 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Oct 2019 · 12 months · monthly snapshot~Oct 2019 – ~Feb 2020 · 4 months · monthly snapshot~Feb 2020 – ~Oct 2020 · 8 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Sep 2023 · 14 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

22 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jul 2022 — Sep 2023 [monthly]

    Completed PHASE2

▶ Show 17 earlier versions

  1. Feb 2022 — Jul 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Dec 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Oct 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2018 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Aug 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  11. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  12. Jan 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  13. Sep 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  14. Jul 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  15. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  16. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Barcelona, Spain , Berlin, Germany , Bethesda, United States , Bordeaux, France , Boston, United States , Chiba, Japan , Copenhagen, Denmark , Freiburg im Breisgau, Germany , Hamburg, Germany and 26 more locations